英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

interdependency    

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
    Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
    Adstiladrin is a prescription medicine for the treatment of adults with a type of cancer of the lining of the bladder called non-muscle invasive bladder cancer (NMIBC), that has not spread to other parts of the body, and that did not respond to treatment with Bacillus Calmette-Guérin (BCG)
  • ADSTILADRIN | FDA
    For the treatment of High-grade, Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer
  • Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
    Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ It is used in adults whose cancer does not respond to treatment with bacillus Calmette-Guérin (BCG) and has a high risk of coming back Nadofaragene firadenovec-vncg is also being studied in the treatment of other types of cancer
  • Ferring Announces Update to NCCN Guidelines Expanding . . .
    ADSTILADRIN ® (nadofaragene firadenovec-vncg) is an FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
  • Adstiladrin | European Medicines Agency (EMA)
    The full indication is: Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours Adstiladrin will be available as a 3 x 10 11 viral particles ml intravesical suspension
  • Adstiladrin (Nadofaragene Firadenovec-vncg): Uses, Side . . .
    Adstiladrin (Nadofaragene Firadenovec-vncg) represents a significant advancement in the treatment of certain types of bladder cancer This innovative gene therapy is designed to address high-risk, non-muscle invasive bladder cancer (NMIBC) that has not responded to standard Bacillus Calmette-Guérin (BCG) therapy Understanding its mechanism, proper administration, and potential side effects
  • Adstiladrin (Nadofaragene Firadenovec-Vncg) for bladder . . .
    Adstiladrin is also called nadofaragene firadenovec-vncg Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells This gene makes a protein called interferon alfa-2b, which activates the immune system to fight cancer cells How do I take it?
  • ADSTILADRIN® in Patients With High-Risk, BCG Unresponsive NMIBC
    The 2024 ASCO annual meeting featured a session on bladder cancer, and a presentation by Dr Min Yang discussing a cost effectiveness analysis of nadofaragene firadenovec for the treatment of high-risk, BCG–unresponsive, non-muscle invasive bladder cancer from a United States third-party payer perspective Read More





中文字典-英文字典  2005-2009